1. Search Result
Search Result
Results for "

polypeptide receptor

" in MedChemExpress (MCE) Product Catalog:

58

Inhibitors & Agonists

1

Fluorescent Dyes

2

Biochemical Assay Reagents

46

Peptides

1

Inhibitory Antibodies

1

Natural
Products

19

Recombinant Proteins

19

Antibodies

2

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P3506
    Retatrutide
    3 Publications Verification

    LY3437943

    GCGR GLP Receptor Metabolic Disease
    Retatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity .
    Retatrutide
  • HY-B0804
    Nadolol
    5 Publications Verification

    SQ-11725

    Adrenergic Receptor Cardiovascular Disease
    Nadolol (SQ-11725) is a non-selective and orally active β-adrenergic receptors blocker and is a substrate of organic anion transporting polypeptide 1A2 (OATP1A2). Nadolol has the the potential for high blood pressure, angina pectoris and vascular headaches research .
    Nadolol
  • HY-P10138
    human GIP(3-30), amide
    1 Publications Verification

    Insulin Receptor Metabolic Disease
    Human GIP(3-30), amide is a high affinity antagonist of the human GIP receptor in vitro. Human GIP(3-30), amide has potential anti-obesity and anti-diabetic effects .
    human GIP(3-30), amide
  • HY-164535

    AMG 133

    Antibody-Drug Conjugates (ADCs) GLP Receptor Insulin Receptor Metabolic Disease
    Maridebart cafraglutide (AMG 133) is a long-acting peptide-antibody conjugate that combines GLP-1 receptor agonist with glucose-dependent insulinotropic polypeptide (GIP) receptor antagonism. Maridebart cafraglutide shows antagonist activity against human, cynomolgus monkey and rat GIPR with IC50 values of 46.4 nM, 26.5 nM, 822.3 nM, respectively. Maridebart cafraglutide shows agonist activity against human, cynomolgus monkey, rat and mouse GLP-1R with EC50 values of 24.4 pM, 5.7 pM, 2.4 pM and 123 pM, respectively. Maridebart cafraglutide can be used for the study of obesity and type 2 diabetes .
    Maridebart cafraglutide
  • HY-P3506A
    Retatrutide TFA
    3 Publications Verification

    LY3437943 TFA

    GLP Receptor GCGR Metabolic Disease
    Retatrutide (LY3437943) TFA is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide TFA binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide TFA can be used for the research of obesity .
    Retatrutide TFA
  • HY-P2542

    Insulin Receptor Metabolic Disease
    GIP (3-42), human acts as a glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist, moderating the insulin secreting and metabolic actions of GIP in vivo .
    GIP (3-42), human
  • HY-P10959

    LY3532226

    Insulin Receptor Metabolic Disease
    Macupatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. Macupatide improves insulin secretion responses and insulin sensitivity.Macupatide can be used for the research of type 2 diabetes .
    Macupatide
  • HY-P990047

    AMG133 antibody

    ADC Antibody GLP Receptor Metabolic Disease
    Maridebart (AMG133 antibody) is a human immunoglobulin G1-kappa, anti-GIPR (gastric inhibitory polypeptide receptor) monoclonal antibody. Maridebart is the antibody portion of Maridebart cafraglutide (HY-164535) and can be used for the synthesis of antibody-drug conjugates (ADC). Maridebart can be used for the reserrch of obesity and type 2 diabetes .
    Maridebart
  • HY-P10735

    Gastric inhibitory polypeptide(mouse); GIP(1-42) (mouse)

    Lipase Apoptosis Metabolic Disease
    GIP (Gastric inhibitory polypeptide) (mouse) is a gastrointestinal hormone that is secreted by the intestinal K cells, and also expressed in and secreted from pancreatic islets. GIP (mouse) promotes insulin secretion from pancreatic β cells via the G-protein-coupled GIP receptor (GIPR). GIP (mouse) promotes pancreatic β cell proliferation and inhibits apoptosis. GIP (mouse) also exerts direct lipogenic effects on adipose tissue .
    GIP (mouse)
  • HY-147557
    PA-915
    1 Publications Verification

    PAC1R antagonist 1

    PACAP Receptor Neurological Disease
    PA-915 (PAC1R antagonist 1) is a potent and orally active antagonist of PAC1 receptor. PA-915 inhibits pituitary adenylate cyclase-activating polypeptide (PACAP)-induced CREB phosphorylation. PA-915 can inhibit PACAP- and nerve injury-induced allodynia. PA-915 can be used for the research of neuropathic pain .
    PA-915
  • HY-P3954

    Somatostatin Receptor Metabolic Disease
    Somatostatin-28 (sheep, human rat mouse) is a biologically active polypeptide, synthesised in the proximal intestinal epithelial cells. Somatostatin-28 (sheep, human rat mouse) suppresses glucose-stimulated insulin secretion without affecting circulating basal insulin concentration. Somatostatin-28 (sheep, human rat mouse) also targets to somatostatin receptor subtype 5 (SSTR5) to regulate GLP-1 secretion .
    Somatostatin-28 (sheep, human rat mouse)
  • HY-P11271

    Insulin Receptor GLP Receptor Metabolic Disease
    Ribupatide is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Enicepatide can be studied in antidiabetic research .
    Ribupatide
  • HY-P0199

    Human pancreatic polypeptide

    Neuropeptide Y Receptor Metabolic Disease Endocrinology
    Pancreatic Polypeptide, human is a C-terminally amidated 36 amino acid peptide, which acts as a neuropeptide Y (NPY) Y4/Y5 receptor agonist.
    Pancreatic Polypeptide, human
  • HY-P0132
    YIGSR
    1 Publications Verification

    Laminin Fragment 929-933

    NO Synthase Cancer
    YIGSR (Laminin Fragment 929-933) is a polypeptide that inhibits tumor growth and metastasis of leukemia cells. YIGSR specifically binds to the 67kDa laminin receptor and regulates the expression of eNOS in endothelial cells. YIGSR can be used in leukemia-related research .
    YIGSR
  • HY-P10138A
    human GIP(3-30), amide TFA
    1 Publications Verification

    Insulin Receptor Metabolic Disease
    Human GIP(3-30), amide TFA is the TFA salt form of human GIP(3-30), amide (HY-P10138). Human GIP(3-30), amide TFA is a high affinity antagonist of the human GIP receptor in vitro. Human GIP(3-30), amide TFA has potential anti-obesity and anti-diabetic effects .
    human GIP(3-30), amide TFA
  • HY-P5005

    CMV PD-1/PD-L1 Infection Inflammation/Immunology Cancer
    VIPhyb is a vasoactive intestinal polypeptide (VIP) receptor antagonist. VIPhyb can inhibit VIP signaling, increase T-cell immunity and downregulate PD1. VIPhyb can inhibit cancer cell proliferation. VIPhyb can reduce inflammatory cytokine expression. VIPhyb can enhance viral clearance. VIPhyb can be used for the researches of cancer, infection and inflammation and immunology, such as non-small cell lung cancer (NSCLC), cytomegalovirus infection and colitis .
    VIPhyb
  • HY-108448

    OLDA

    TRP Channel Lipoxygenase Cardiovascular Disease Neurological Disease Metabolic Disease
    N-Oleoyldopamine (OLDA) is an orally active TRPV1 activator and 5-LOX inhibitor with blood-brain barrier permeability. N-Oleoyldopamine excites histaminergic neurons in the tuberomammillary nucleus via a dopamine receptor mechanism, a process independent of TRPV1 and cannabinoid receptors. On one hand, N-Oleoyldopamine promotes the release of insulin and glucose-dependent insulinotropic polypeptide through a GPR119-dependent pathway to improve glucose tolerance; on the other hand, N-Oleoyldopamine improves left ventricular function and reduces myocardial infarction size by triggering the release of substance P and calcitonin gene-related peptide. N-Oleoyldopamine is used in studies related to glycemic abnormalities and myocardial ischemia-reperfusion injury .
    N-Oleoyldopamine
  • HY-P10271

    NNC0090-2746; MAR709; RO6811135

    GLP Receptor Metabolic Disease
    RG7697 is a dual agonist for glucagon-like peptide receptor (GLP Receptor) and glucosedependent insulinotropic polypeptide receptor (GIPR), with EC50 of 5 and 3 pM, respectively. RG7697 exhibits antihyperglycemic property .
    RG7697
  • HY-177204

    Ferroptosis Apoptosis Glutathione Peroxidase Cardiovascular Disease
    DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW is a polypeptide targeting tenascin-X (Tenascin-X) that can be conjugated with liposomes and exosomes. DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW specifically binds to Tenascin-X on the surface of cardiomyocytes, mediates receptor-dependent uptake of nanocarriers, enhances targeted drug delivery of cargo to cardiomyocytes, and increases drug accumulation in cardiac tissue. DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW protects cardiomyocytes treated with LPS, alleviates oxidative stress, repairs mitochondrial function, inhibits ferroptosis and apoptosis, and downregulates the secretion of pro-inflammatory cytokines at the same time. DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW improves cardiac injury and pathological morphology in mice with sepsis-induced cardiomyopathy, restores GPX4 expression, and promotes the internalization of cardiomyocyte-derived exosomes, making it suitable for related research on sepsis-induced cardiomyopathy, myocardial ischemia-reperfusion injury, and other conditions .
    DSPE-PEG2000-WLSEAGPVVTVRALRGTGSW
  • HY-P0089A

    Growth Hormone Releasing Factor human TFA; Somatorelin (1-44) amide (human) TFA

    GHSR Endocrinology
    Human growth hormone-releasing factor TFA (Growth Hormone Releasing Factor human TFA) is a hypothalamic polypeptide and stimulates GH production and release by binding to the GHRH Receptor (GHRHR) on cells in the anterior pituitary .
    Human growth hormone-releasing factor TFA
  • HY-P1072

    CGRP Receptor Cardiovascular Disease Metabolic Disease
    PHM-27 (human) is a human prepro-vasoactive intestinal polypeptide (27 amino acid). PHM-27 (human) is a potent the human calcitonin receptor agonist with an EC50 of 11 nM. PHM-27 (human) efficiently enhances glucose-induced insulin secretion from beta cells by an autocrine mechanism .
    PHM-27 (human)
  • HY-P11288

    PACAP Receptor Apoptosis Cancer
    ANT308 is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 significantly enhances the activation and proliferation of T cells. ANT308 inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 can be used for the studies of acute myeloid leukemia (AML) and uveal melanoma (UVM) .
    ANT308
  • HY-P11288A

    PACAP Receptor Apoptosis Cancer
    ANT308 TFA is a vasoactive intestinal polypeptide (VIP receptor) antagonist. ANT308 TFA significantly enhances the activation and proliferation of T cells. ANT308 TFA inhibits the migration and metastasis, induces apoptosis of melanoma tumor cells by inhibiting VIP-VPAC2 signaling and reducing the expression of MCAM and N-cadherin. ANT308 TFA can be used for the study of acute myeloid leukemia (AML) and uveal melanoma (UVM) .
    ANT308 TFA
  • HY-153650

    Natriuretic Peptide Receptor (NPR) Others
    JS11 is an inhibitor for natriuretic polypeptide receptor 1 (Npr1) with an IC50 of 1.9 μM for hNpr1. JS11 ameliorates the pruritus in mouse models .
    JS11
  • HY-P10959A

    LY3532226 acetate

    Insulin Receptor Metabolic Disease
    Macupatide acetate is a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. Macupatide acetate improves insulin secretion responses and insulin sensitivity.Macupatide acetate can be used for the research of type 2 diabetes .
    Macupatide acetate
  • HY-P2541A

    Insulin Receptor Metabolic Disease
    GIP (1-30) amide, porcine TFA is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.
    GIP (1-30) amide, porcine TFA
  • HY-139201C

    PDLHB (MW 1000-5000)

    CaSR Others
    Poly-D-lysine hydrobromide (MW 1000-5000) (PDLHB (MW 1000-5000)) is a synthetic cationic polypeptide polymer commonly used as a cell adhesion promoter and surface coating molecule. Poly-D-lysine hydrobromide is also known as a calcium-sensing receptor (CaSR) agonist peptide .
    Poly-D-lysine hydrobromide (MW 1000-5000)
  • HY-129421

    PACAP Receptor Neurological Disease Inflammation/Immunology
    PA-9 is a pituitary adenylate cyclase-activating polypeptide (PACAP) type I (PAC1) receptor antagonist. PA-9 dose dependently inhibits PACAP-induced cAMP elevation with an IC50 of 5.6 nM. PA-9 can be used for the research of neuropathic and/or inflammatory pain .
    PA-9
  • HY-P4195A

    IPK Superfamily Metabolic Disease
    [K15,R16,L27]VIP(1-7)/GRF(8-27) (acetate) is the acetate of [K15,R16,L27]VIP(1-7)/GRF(8-27) (HY-P4195). [K15,R16,L27]VIP(1-7)/GRF(8-27) (acetate), a VIP1 selective agonist, exhibits IC50 values of binding of 2 nM, 1 nM, 30,000 nM for the human VIP1, rat VIP1, rat VIP2 receptors, respectively . VIP: VASOACTIVE Intestinal Polypeptide
    [K15,R16,L27]VIP(1-7)/GRF(8-27) acetate
  • HY-P3506B

    LY3437943 acetate

    GCGR GLP Receptor Metabolic Disease
    Retatrutide (LY3437943) acetate is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide acetate inhibits human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide acetate can be used for the research of obesity .
    Retatrutide acetate
  • HY-P10591

    Olatorepatidum

    Insulin Receptor GLP Receptor Metabolic Disease
    Olatorepatide (Olatorepatidum) is a dual gastric inhibitory polypeptide (GIP) receptor and glucagon like peptide 1 (GLP-1) receptor agonist, with antidiabetic effect .
    Olatorepatide
  • HY-P11271A

    Insulin Receptor GLP Receptor Metabolic Disease
    Ribupatide TFA is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Ribupatide TFA can be studied in antidiabetic research .
    Ribupatide TFA
  • HY-P1532

    Rat pancreatic polypeptide

    Neuropeptide Y Receptor Metabolic Disease Endocrinology
    Pancreatic Polypeptide, rat is an agonist of NPY receptor, with high affinity at NPYR4.
    Pancreatic Polypeptide, rat
  • HY-P4060A

    Neuropeptide Y Receptor Others
    Pancreatic polypeptide TFA is a neuropeptide Y (NPY) Y4/Y5 receptor agonist.
    Pancreatic polypeptide TFA
  • HY-P11237

    CT-388

    GCGR Insulin Receptor Metabolic Disease
    Enicepatide is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Enicepatide can be studied in antidiabetic research .
    Enicepatide
  • HY-P11270

    BG128

    Insulin Receptor GLP Receptor Metabolic Disease
    Relsipatide (BG128) is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Enicepatide can be studied in antidiabetic research .
    Relsipatide
  • HY-P0089

    Growth Hormone Releasing Factor human; Somatorelin (1-44) amide (human)

    GHSR Endocrinology
    Human growth hormone-releasing factor (Growth Hormone Releasing Factor human) is a hypothalamic polypeptide and stimulates GH production and release by binding to the GHRH Receptor (GHRHR) on cells in the anterior pituitary .
    Human growth hormone-releasing factor
  • HY-P1324

    Neuropeptide Y Receptor Neurological Disease
    [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic Polypeptide is a potent and selective neuropeptide Y Y5 receptor agonist with an IC50 of 0.24 nM for binding to the hY5 receptor. [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic Polypeptide induces a high amount of food intake .
    [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic Polypeptide
  • HY-P2537
    Apelin-12
    2 Publications Verification

    HIV Apelin Receptor (APJ) Others
    Apelin-12 is one of the most potent C-terminal fragments of the polypeptide that possesses a high affinity to orphan receptor APJ receptor. Apelin-12 is involved in the regulation of body fluid homeostasis and in the central control of feeding. Apelin-12 blocks HIV-1 entry through APJ receptor. Apelin-12 exerts neuroprotective effect .
    Apelin-12
  • HY-P1537

    Neuropeptide Y Receptor Metabolic Disease Endocrinology
    Pancreatic Polypeptide, bovine, a 36-amino acid, straight chain polypeptide derived primarily from the pancreas, inhibits secretin- and cholecystokinin-stimulated pancreatic secretion; Pancreatic Polypeptide, bovine acts as an agonist of NPY receptor, with high affinity at NPYR4.
    Pancreatic Polypeptide, bovine
  • HY-W013781

    Biochemical Assay Reagents Others
    Boc-Glu(OBzl)-OH (Compound 9) is a glutamic acid derivative commonly used in Boc SPPS. Glutamic acid residues increase the hydrophilicity of the polypeptide and play an important structural and receptor binding role .
    Boc-Glu(OBzl)-OH
  • HY-P2541

    Insulin Receptor Metabolic Disease
    GIP (1-30) amide, porcine is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42) . GIP (1-30) amide, porcine is a weak inhibitor of gastric acid secretion and potent stimulator of insulin.
    GIP (1-30) amide, porcine
  • HY-B0804R

    SQ-11725 (Standard)

    Reference Standards Adrenergic Receptor Cardiovascular Disease
    Nadolol (Standard) is the analytical standard of Nadolol. This product is intended for research and analytical applications. Nadolol (SQ-11725) is a non-selective and orally active β-adrenergic receptors blocker and is a substrate of organic anion transporting polypeptide 1A2 (OATP1A2). Nadolol has the the potential for high blood pressure, angina pectoris and vascular headaches research .
    Nadolol (Standard)
  • HY-P2057

    Endothelin Receptor Cardiovascular Disease
    PD 142893 is a endothelin-B receptor antagonist .
    PD 142893
  • HY-P3867

    Orexin Receptor (OX Receptor) Apoptosis Cancer
    Hypocretin (70-98), human is a polypeptide that is capable of binding to an orexin receptor OX1R and promotes apoptosis .
    Hypocretin (70-98), human
  • HY-P4129

    nAChR Others
    Rabies Virus Matrix Protein Fragment (RV-MAT) is a polypeptide. Rabies Virus Matrix Protein Fragment targets the acetylcholine receptor (AChR) that exists on the cell surface .
    Rabies Virus Matrix Protein Fragment(RV-MAT)
  • HY-P1324A

    Neuropeptide Y Receptor Neurological Disease
    [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic Polypeptide is a potent and selective neuropeptide Y Y5 receptor agonist with an IC50 of 0.24 nM for binding to the hY5 receptor. [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic Polypeptide induces a high amount of food intake .
    [cPP1-7,NPY19-23,Ala31,Aib32,Gln34]-hPancreatic polypeptide TFA
  • HY-N5159

    iGluR Neurological Disease
    Ampullosporin A is a peptaibol-type polypeptide that can be isolated from the fungus Sepedonium ampullosporum HKI-0053, exhibiting neuroleptic-like activity. Ampullosporin A can inhibit hyperactivity induced by NMDA receptor antagonist MK-801 (HY-15084B) and ameliorate social behavior abnormalities caused by subchronic drug treatment. Ampullosporin A alters the activity of glutamate receptors without affecting dopamine D1 and D2 receptors .
    Ampullosporin A
  • HY-174744

    mRNA Inflammation/Immunology
    Human CCR4 mRNA encodes the human C-C motif chemokine receptor 4 (CCR4) protein, a member of G protein-coupled receptors family. CCR4 is a receptor for the CC chemokine - MIP-1, RANTES, TARC and MCP-1. Chemokines are a group of small polypeptide, structurally related molecules that regulate cell trafficking of various types of leukocytes. The chemokines also play fundamental roles in the development, homeostasis, and function of the immune system, and they have effects on cells of the central nervous system as well as on endothelial cells involved in angiogenesis or angiostasis.
    Human CCR4 mRNA
  • HY-P4195

    IPK Superfamily Metabolic Disease
    [K15,R16,L27]VIP(1-7)/GRF(8-27), a VIP1 selective agonist, exhibits IC50 values of binding of 2 nM, 1 nM, 30,000 nM for the human VIP1, rat VIP1, rat VIP2 receptors, respectively . VIP: VASOACTIVE Intestinal Polypeptide
    [K15,R16,L27]VIP(1-7)/GRF(8-27)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: